Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our clinical expertise and differentiated approach enables us to advance best-in -class and/or first-in-class therapies that have the potential to transform the treatment landscape for protein dysregulation diseases |
| The ongoing confirmatory AFFIRM AL trial was designed based on a SPA agreement with the FDA to approve Birtamimab at a p-value of less than or equal to 0.1 for the primary endpoint of all-cause mortality showing an early and sustained impact on mortality is a powerful differentiator and If approved we are confident that Birtamimab will be welcomed as a major advancement in the field and a key treatment option |
| And again, very strong enrollment and people are very excited about the one [Indiscernible] placebo-controlled, where placebo patients will now receive a drug of course that will be the first – the other patients will continue to go on down to 12 months of potential treatment of PRX12, which we are capturing both safety and tolerability and of course PK and pharmacodynamic measurement |
| As Gene mentioned during his opening remarks, our robust portfolio of wholly-owned and strategically partnered programs allows us to leverage partner payments while still maintaining full upside potential of our wholly-owned programs |
| This intentional mix allows us to advance a fulsome portfolio by leveraging the benefits of working with key strategic partners on some programs, while still maintaining the full upside potential for our wholly-owned programs where we feel that we have unique insight and expertise |
| As we look ahead, we're excited to have meaningful catalysts across our programs with potential clinical readouts from four ongoing clinical trials within the next 12 to 18 months, which include top-line results from our confirmatory AFFIRM AL Phase 3 trial evaluating Birtamimab in patients with MAYO stage IV AL amyloidosis, clinical data from our ongoing phase 1 trial evaluated PRX 12 as a potential best-in-class treatment in early Alzheimer's disease, top-line results from the Phase 2b PADOVA trial evaluating Prasinezumab for Parkinson's disease being conducted by Roche |
| So I think what that could indicate is that we believe that the therapeutic index provides us with the sense that we have the potential for a best-in-class molecule |
| PRX12 was designed with the patient in mind and we believe it has the potential to be best-in-class transforming the treatment of Alzheimer's disease by meaningfully reducing treatment burden associated with the currently available anti data therapies |
| The market dynamics for Birtamimab as our potential first commercial product are quite compelling |
| So we've been affording also the opportunity to include a number of cohorts and we've been able to enroll those cohorts in a pretty favorable way |
| We remain well-funded to execute on our strategic objectives taking us well beyond our upcoming clinical readouts |
| This is an exciting year of clinical trial execution for both Prothena and our strategic partners |
| Enrollemnt is very strong in our PRX12 Signal trial |
| This was further supported by meaningful and significant improvements in functions as measured by six-minute walk test and quality of life as measured by SF-36 |
| Our plan is to independently commercialize Birtamimab and we believe that we will be able to efficiently reach prescribers for advanced patients with a focused commercial presence |
| We are well-capitalized with a robust cash position and remain focused on advancing our clinical programs as we strive to become a fully integrated commercial biotechnology company |
| I am proud of the progress that Prothena made in 2023 and continued into 2024 |
| The capital MAYO curve illustrating the separation is shown here on Slide 12 demonstrating an early and sustained benefits |
| That mission is enabled by our deep scientific expertise, which serves as a unifying trend connecting our corporate strategy, our portfolio development and the dedication that propels opinions every day |
| As you will hear about more detail later in this call, we ended 2023 with a strong cash position of $621 million |
| We continue to advance our mission which has fueled our robust late-stage clinical pipeline moving us closer to becoming a fully integrated commercial biotechnology company |
| So we're excited to see those results |
| Our own going Neuroscience R&D collaboration with CMS made meaningful advancements in 2023 and into this year |
| And obviously also continued conversations between our partners at Rocha and the regulators and we have very high confidence that Roche will be as a aggressive as is appropriate based on the data set that they have today |
| This mechanism of action has a potential benefit for ATTR patients at high risk for early mortality due to amyloid deposition in vital organs |
| Our team continues to build upon the existing relationships we've established for KOLs and experts in the field through our extensive clinical programs for Birtamimab |
| BMS 986446 formerly PRX005 is a potential best-in-class antibody for the treatment of Alzheimer's disease that specifically targets the key episodes within the microtubule binding region of tau |
| Based on our market research, we understand that a treatment with similar efficacy and safety to currently approved anti-beta therapies, but delivered as a once monthly at home subcutaneous treatment has potential to be the dominant player in the market |
| We’ve demonstrated a high potent binding, high affinity and avidity and a slow off rate allowing for considered target engagement, all of which are optimal for once monthly subcutaneous treatment |
| The preclinical data combined with the initial clinical data from our ongoing Phase 1 trial are supportive of a once monthly, subcutaneous treatment with a potential best-in-class profile |
| Statement |
|---|
| You've got a lot going on and limiting to one question will be a challenge |
| Although, that being said, there clearly as if those effect relationship within molecules, but between molecules, there's a little bit of a difference and we continue to believe that Aria is a mechanistically-driven event meaning if you are removing plaque, you're going to increase the risk of this observing Aria |
| Obviously that's less than ideal as we start to think forward to efficacy-driven studies and registrational studies |
| This remains a serious unmet need for patients and their families |
| Without their support we could not elucidate the potential impacts of the new medicines we’re developing |
Please consider a small donation if you think this website provides you with relevant information